Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Symmetry Surgical, a subsidiary of orthopedic implants and instruments maker Symmetry Medical, Inc. (SMA - Analyst Report), recently signed a distribution agreement with renowned UK-based healthcare company, Hospital Innovations. As per the terms of the deal, Hospital Innovations will distribute Symmetry Surgical’s surgical instruments in UK.
Hospital Innovations distributes cutting-edge medical devices to about 400 hospitals across UK. The partnership will enable Symmetry Surgical to grow its customer base in the European market.
The distribution agreement is in line with Symmetry Surgical’s focus on worldwide expansion of its business inclusive of all brands under the erstwhile Codman Surgical Instruments. The company further plans to expand into other key European countries to gain healthy revenue opportunities.
Since Symmetry Medical’s core Original Equipment Manufacturer (“OEM”) Solutions business is facing declining capital spending, procedural and pricing pressure from the weak global orthopedic market, the company is focused on expanding its smaller Symmetry Surgical business.
Earlier, in Nov 2012, Symmetry Surgical collaborated with leading medical device distributor, MTG Medical Technologies (“MTG”) to sell its offerings in Europe. MTG, a subsidiary of Neuro-Competence, distributes cutting-edge yet affordable medical devices to hospitals located across Germany, Austria, Switzerland, Czech Republic, Hungary and Slovakia.
In the fourth quarter of 2012, revenues from the smaller Symmetry Surgical unit jumped 154% to $28.5 million, buoyed by the acquisition of Codman & Shurtleff, Inc., which contributed roughly $13.1 million to the division’s sales. Revenues also include a one-time purchase of an OEM Solutions client worth $2.9 million. Excluding the acquisition and the one-time purchase, sales increased 10.4% year over year in the quarter.
However, the company currently has a Zacks Rank #4 (Sell), as both revenues and earnings missed the Zacks Consensus Estimates in the fourth quarter of 2012. While we remain on the sidelines regarding Symmetry, companies such as Nuvasive Inc. (NUVA - Snapshot Report), Essilor International SA (ESLOY) and Cyberonics Inc. (CYBX - Analyst Report), each carrying a Zacks Rank #1 (Strong Buy), warrant a look.
Get the full Analyst Report on SMA - FREE
Get the full Analyst Report on CYBX - FREE
Get the full Snapshot Report on NUVA - FREE
Get the full on ESLOY - FREE